vs
FENNEC PHARMACEUTICALS INC.（FENC）与Simulations Plus, Inc.（SLP）财务数据对比。点击上方公司名可切换其他公司
Simulations Plus, Inc.的季度营收约是FENNEC PHARMACEUTICALS INC.的1.3倍（$18.4M vs $13.8M），Simulations Plus, Inc.净利率更高（3.7% vs -34.7%，领先38.4%），FENNEC PHARMACEUTICALS INC.同比增速更快（73.8% vs -2.7%），过去两年Simulations Plus, Inc.的营收复合增速更高（0.3% vs -26.3%）
Fennec制药是一家生物制药企业，专注于开发和商业化可降低儿童癌症患者治疗相关副作用的特种疗法，核心产品针对化疗引发的耳毒性，主要市场覆盖北美，服务肿瘤诊疗机构及儿童肿瘤患者群体。
Simulations Plus公司为医药生物、化工、化妆品、食品原料及除草剂领域开发ADMET（吸收、分布、代谢、排泄和毒性）建模仿真软件，并于2014年9月收购了提供临床试验数据分析及咨询服务的Cognigen公司，助力相关行业研发工作开展。
FENC vs SLP — 直观对比
营收规模更大
SLP
是对方的1.3倍
$13.8M
营收增速更快
FENC
高出76.5%
-2.7%
净利率更高
SLP
高出38.4%
-34.7%
两年增速更快
SLP
近两年复合增速
-26.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.8M | $18.4M |
| 净利润 | $-4.8M | $676.0K |
| 毛利率 | — | 59.1% |
| 营业利润率 | -18.5% | 3.9% |
| 净利率 | -34.7% | 3.7% |
| 营收同比 | 73.8% | -2.7% |
| 净利润同比 | -141.1% | 228.2% |
| 每股收益（稀释后） | $-0.17 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FENCSLP
| Q4 25 | $13.8M | $18.4M | ||
| Q3 25 | $12.5M | $17.5M | ||
| Q2 25 | $9.7M | $20.4M | ||
| Q1 25 | $8.8M | $22.4M | ||
| Q4 24 | $7.9M | $18.9M | ||
| Q3 24 | $7.0M | $18.7M | ||
| Q2 24 | $7.3M | $18.5M | ||
| Q1 24 | $25.4M | $18.3M |
净利润FENCSLP
| Q4 25 | $-4.8M | $676.0K | ||
| Q3 25 | $-638.0K | $-681.0K | ||
| Q2 25 | $-3.2M | $-67.3M | ||
| Q1 25 | $-1.2M | $3.1M | ||
| Q4 24 | $-2.0M | $206.0K | ||
| Q3 24 | $-5.7M | $843.0K | ||
| Q2 24 | $-5.6M | $3.1M | ||
| Q1 24 | $12.8M | $4.0M |
毛利率FENCSLP
| Q4 25 | — | 59.1% | ||
| Q3 25 | — | 56.4% | ||
| Q2 25 | — | 64.0% | ||
| Q1 25 | — | 58.5% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 71.5% | ||
| Q1 24 | — | 72.2% |
营业利润率FENCSLP
| Q4 25 | -18.5% | 3.9% | ||
| Q3 25 | -1.5% | 3.8% | ||
| Q2 25 | -28.3% | -364.5% | ||
| Q1 25 | -9.2% | 12.1% | ||
| Q4 24 | -11.8% | 0.7% | ||
| Q3 24 | -74.6% | -6.2% | ||
| Q2 24 | -69.4% | 10.1% | ||
| Q1 24 | 54.2% | 24.3% |
净利率FENCSLP
| Q4 25 | -34.7% | 3.7% | ||
| Q3 25 | -5.1% | -3.9% | ||
| Q2 25 | -32.7% | -330.6% | ||
| Q1 25 | -13.3% | 13.7% | ||
| Q4 24 | -25.0% | 1.1% | ||
| Q3 24 | -82.2% | 4.5% | ||
| Q2 24 | -76.5% | 16.9% | ||
| Q1 24 | 50.6% | 22.0% |
每股收益（稀释后）FENCSLP
| Q4 25 | $-0.17 | $0.03 | ||
| Q3 25 | $-0.02 | $-0.03 | ||
| Q2 25 | $-0.11 | $-3.35 | ||
| Q1 25 | $-0.04 | $0.15 | ||
| Q4 24 | $-0.02 | $0.01 | ||
| Q3 24 | $-0.21 | $0.04 | ||
| Q2 24 | $-0.20 | $0.15 | ||
| Q1 24 | $0.41 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $36.8M | $35.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $35.5M | $127.1M |
| 总资产 | $70.6M | $137.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FENCSLP
| Q4 25 | $36.8M | $35.7M | ||
| Q3 25 | $21.9M | $32.4M | ||
| Q2 25 | $18.7M | $28.4M | ||
| Q1 25 | $22.7M | $21.4M | ||
| Q4 24 | $26.6M | $18.2M | ||
| Q3 24 | $40.3M | $20.3M | ||
| Q2 24 | $43.1M | $119.0M | ||
| Q1 24 | $51.2M | $108.5M |
总债务FENCSLP
| Q4 25 | — | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $31.3M | — |
股东权益FENCSLP
| Q4 25 | $35.5M | $127.1M | ||
| Q3 25 | $-4.5M | $124.8M | ||
| Q2 25 | $-7.5M | $123.8M | ||
| Q1 25 | $-5.9M | $189.5M | ||
| Q4 24 | $-5.9M | $184.7M | ||
| Q3 24 | $-5.2M | $182.4M | ||
| Q2 24 | $-1.4M | $180.9M | ||
| Q1 24 | $3.0M | $177.0M |
总资产FENCSLP
| Q4 25 | $70.6M | $137.8M | ||
| Q3 25 | $49.3M | $131.9M | ||
| Q2 25 | $44.9M | $134.4M | ||
| Q1 25 | $46.4M | $201.4M | ||
| Q4 24 | $44.9M | $196.9M | ||
| Q3 24 | $58.9M | $196.6M | ||
| Q2 24 | $63.2M | $192.7M | ||
| Q1 24 | $69.2M | $194.0M |
负债/权益比FENCSLP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.0M | $4.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | 6.26× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FENCSLP
| Q4 25 | $-6.0M | $4.2M | ||
| Q3 25 | $1.5M | $5.6M | ||
| Q2 25 | $-3.7M | $8.1M | ||
| Q1 25 | $-4.3M | $5.7M | ||
| Q4 24 | $-1.5M | $-1.3M | ||
| Q3 24 | $-2.2M | $1.7M | ||
| Q2 24 | $-8.4M | $5.7M | ||
| Q1 24 | $39.0M | $5.8M |
自由现金流FENCSLP
| Q4 25 | — | — | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $5.6M | ||
| Q4 24 | — | $-1.4M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $5.6M | ||
| Q1 24 | — | $5.4M |
自由现金流率FENCSLP
| Q4 25 | — | — | ||
| Q3 25 | — | 30.5% | ||
| Q2 25 | — | 38.5% | ||
| Q1 25 | — | 25.0% | ||
| Q4 24 | — | -7.2% | ||
| Q3 24 | — | 8.8% | ||
| Q2 24 | — | 30.0% | ||
| Q1 24 | — | 29.4% |
资本支出强度FENCSLP
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.6% | ||
| Q1 24 | — | 2.4% |
现金转化率FENCSLP
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.84× | ||
| Q4 24 | — | -6.18× | ||
| Q3 24 | — | 1.97× | ||
| Q2 24 | — | 1.81× | ||
| Q1 24 | 3.04× | 1.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FENC
暂无分部数据
SLP
| Services Segment | $9.5M | 52% |
| Development | $7.2M | 39% |
| Discovery | $1.3M | 7% |
